(Total Views: 410)
Posted On: 03/29/2018 12:58:36 PM
Post# of 72445
20 CDAs.
I would suspect that IPIX, being a very small company, is tightly controlled and run by the big three executives (LE, KM, and AB). It's hard waiting on the Prurisol results because it feels like time is wasting away. There currently are no other trials going on so it feels like everyone is waiting with baited breath for the Prurisol results and some kind of deal.
Now, we definitely have development and preclinical work going on. Oral K, B-OM sachet development, B-UP formulation/delivery optimization, B topical development, etc. just to name a few. Exploration of other Brilacidin uses are occurring at the preclinical stage (Acne, HS, Eczema, AD, etc.) as well. So there is tons of progress being made though it may be less flashy than the flurry of phase 2 trials that were the hallmark of 2016/2017.
What else is going on though? 20+ CDAs. Possibly more at this point in time. How much work on a daily basis do you think feeding information to/from 20+ CDA holders is? It likely all has to go through two or three men on the IPIX side. Even if each CDA gets one update a month, on average that is an update every single business day. If there are terms sheets and negotiations going on as well the back and forth would be significant. I suspect our executives are up to their necks in communications and negotiations and the intensity is increasing by the day.
Time is not standing still friends. The delivery development, preclinical development and CDA negotiations are a sea of value rising up around the pillars of our clinical trial successes. The storm surge is coming and will catch many off guard. Have your boats ready and stocked. The tsunami approaches.
I would suspect that IPIX, being a very small company, is tightly controlled and run by the big three executives (LE, KM, and AB). It's hard waiting on the Prurisol results because it feels like time is wasting away. There currently are no other trials going on so it feels like everyone is waiting with baited breath for the Prurisol results and some kind of deal.
Now, we definitely have development and preclinical work going on. Oral K, B-OM sachet development, B-UP formulation/delivery optimization, B topical development, etc. just to name a few. Exploration of other Brilacidin uses are occurring at the preclinical stage (Acne, HS, Eczema, AD, etc.) as well. So there is tons of progress being made though it may be less flashy than the flurry of phase 2 trials that were the hallmark of 2016/2017.
What else is going on though? 20+ CDAs. Possibly more at this point in time. How much work on a daily basis do you think feeding information to/from 20+ CDA holders is? It likely all has to go through two or three men on the IPIX side. Even if each CDA gets one update a month, on average that is an update every single business day. If there are terms sheets and negotiations going on as well the back and forth would be significant. I suspect our executives are up to their necks in communications and negotiations and the intensity is increasing by the day.
Time is not standing still friends. The delivery development, preclinical development and CDA negotiations are a sea of value rising up around the pillars of our clinical trial successes. The storm surge is coming and will catch many off guard. Have your boats ready and stocked. The tsunami approaches.
(5)
(0)
The Ghost of Phteven. All posts my opinion and speculation only.
